8月28日 - ** 制药公司Cytokinetics（CYTK.O）的股价在盘前交易中上涨1.7%，至79.27美元
** CYTK表示，详细后期临床试验数据 (link) 显示，其药物aficamten显著改善了患有某种遗传性心脏病患者的症状和运动能力，而该病目前尚无获批的治疗方法
** 该药物已获批作为Myqorzo用于治疗oHCM——即阻塞性肥厚型心肌病（hypertrophic cardiomyopathy），该病症因心肌增厚而阻碍血流
**在oHCM领域，Myqorzo与百时美施贵宝（Bristol Myers Squibb）的 BMY.N Camzyos形成竞争
** 该公司正寻求将该药的适应症扩展至非梗阻型肥厚型心肌病（nHCM），该病症会导致心肌增厚但不阻塞血流
** 截至上一交易日收盘，CYTK股价年内累计上涨22.6%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.